Moreover, BV has demonstrated rapid effectiveness in LCT MF with CD30 expression, serving as a bridge to allogeneic stem cell transplantation (ASCT), and it can be used during the resumption after ASCT in case of disease recurrence [57]. The gene discussed is TNFRSF8; the disease is mycosis fungoides.